BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc to Discuss Proof-of-Concept Data for Encaleret in Autosomal Dominant Hypocalcemia Type 1 Transcript

Mar 22, 2021 / 12:00PM GMT
Release Date Price: $69.11 (+2.14%)
Operator

Good morning, ladies Ladies and gentlemen, and welcome to BridgeBio Pharma's call to discuss proof-of-concept data for encaleret and ADH1. (Operator Instructions). As a reminder, today's conference call is being recorded.

I'd now like to turn the conference over to your host, Dr. Neil Kumar, Founder and CEO of BridgeBio Pharma. Please go ahead.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Thank you, operator, and thanks, everyone, for joining today's call. Before I dive in, I have to do the customary forward-looking statement here. So before we begin, I'll remind everyone that this presentation is being webcast and includes forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. You all know the rest.

So let's dive in. The purpose of today's call, which I hope is clear, is to discuss the positive and extremely encouraging data that were released this weekend at ENDO, detailing the latest in our efforts that many of you know about to treat autosomal

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot